News - Celgene

Filter

Current filters:

Celgene

Popular Filters

19 to 43 of 91 results

OncoMed rockets on possible multi-billion dollar deal with Celgene

OncoMed rockets on possible multi-billion dollar deal with Celgene

04-12-2013

US biotech companies OncoMed Pharmaceuticals and Celgene have entered an agreement to jointly develop…

Anti-DLL4BiotechnologyCelgenedemcizumabLicensingMergers & AcquisitionsOMP-21M18OncologyOncoMed PharmaceuticalsResearch

Celgene’s Abraxane gets positive CHMP opinion for pancreatic cancer

Celgene’s Abraxane gets positive CHMP opinion for pancreatic cancer

29-11-2013

US biotech company Celgene’s (Nasdaq: CELG) European subsidiary has received a positive opinion from…

AbraxaneCelgeneEuropeOncologyPharmaceuticalRegulation

Celgene 3rd-qtr beats expectations; raises earnings guidance

25-10-2013

US biotech company Celgene Corp reported third quarter 2013 total revenue of $1.67 billion compared to…

BiotechnologyCelgeneFinancialHematologyOncology

Negative draft NICE guidance on Celgene’s Revlimid for myelodysplastic syndromes

24-10-2013

The UK drug watchdog the National Institute for Health and Care Excellence (NICE) today issued final…

BiotechnologyCelgeneEuropeOncologyRegulationRevlimid

Abraxane shows increased survival in metastatic pancreatic cancer

Abraxane shows increased survival in metastatic pancreatic cancer

17-10-2013

Celgene International, a wholly-owned subsidiary of Celgene Corp, has announced the results of the MPACT…

AbraxaneCelgeneNorth AmericaOncologyPharmaceuticalResearch

PharmAkea, Celgene and Bay City Capital collaborate on cancer and fibrotic disease

PharmAkea, Celgene and Bay City Capital collaborate on cancer and fibrotic disease

09-10-2013

PharmAkea Therapeutics and Bay City Capital have entered a strategic collaboration with Celgene designed…

BiotechnologyCelgeneMergers & AcquisitionsNorth AmericaOncologyPharmAkeaResearch

US FDA backs Abraxane for metastatic pancreatic cancer

09-09-2013

US biotech firm Celgene (Nasdaq: CELG) said on Friday (September 6) that the US Food and Drug Administration…

AbraxaneBiotechnologyCelgenegemcitabine HclNorth AmericaOncologyRegulation

Celgene's pomalidomide meets primary endpoint in multiple myeloma

05-09-2013

US biotech major Celgene (Nasdaq: CELG) announced that positive updated results from MM-003, a Phase…

BiotechnologyCelgeneImnovidOncologypomalidomidePomalystResearch

Adimab enters collaborations with Celgene and Innovent; gets milestones

21-08-2013

USA-based therapeutic antibody developer Adimab this week announced two new collaborations, one with…

AdimabBiotechnologyCelgeneInnovent BiologicsLicensingResearch

Epizyme's leukemia compound granted orphan drug designation

19-08-2013

US biotech company Epizyme (NASDAQ: EPZM) has been granted orphan drug designation for its experimental…

BiotechnologyCelgeneEpizymeNorth AmericaOncologyRegulation

MorphoSys closes on the alliance with Celgene

14-08-2013

German biotech firm MorphoSys (FSE: MOR) that its MOR202 alliance with Celgene (Nasdaq: CELG), the world's…

BiotechnologyCelgeneFinancialLicensingMOR202MorphoSysOncology

Pomalidomide Celgene OKed in Europe

09-08-2013

The European Commission has granted approval for US biotech firm Celgene's (Nasdaq: CELG) Pomalidomide…

BiotechnologyCelgeneEuropeImnovidOncologypomalidomidePomalidomide CelgeneRegulation

Three-year survival improves in SMM patients treated with Revlimid, study shows

02-08-2013

US biotech firm Celgene (Nasdaq: CELG) has released positive new data evaluating treatment with Revlimid…

CelgeneNorth AmericaOncologyPharmaceuticalResearchRevlimid

Array BioPharma signs up to $387 million deal

30-07-2013

In a second licensing deal this week US biotech major Celgene (Nasdaq: CELG) has entered into a strategic…

Array BioPharmaBiotechnologyCelgeneInflammatory diseasesLicensing

Acetylon snags $100 million upfront cash and acquisition option

30-07-2013

Privately-held Acetylon and US biotech firm Celgene (Nasdaq: CELG) have entered into an exclusive strategic…

Acetylon PharmaceuticalsBiotechnologyCelgeneLicensingMergers & AcquisitionsNeurologicalOncology

Celgene's 2nd-qtr results and forecasts beat expectations

25-07-2013

Shares of US biotech Celgene (Nasdaq: CELG) rose 1.6% in pre-market trading this morning (July 25), as…

BiotechnologyCelgeneFinancial

Celgene halts blood cancer drug trial

19-07-2013

US biotech major Celgene Corp (Nasdaq: CELG) said yesterday (July 18) that, after consultation with the…

BiotechnologyCelgeneOncologyResearchRevlimid

Celgene gets negative NICE view on Revlimid in rare blood cancer; presents new data in newly-diagnosed MM

11-07-2013

US biotech firm Celgene (Nasdaq: CELG) today (July 11) expressed disappointment at the preliminary decision…

BiotechnologyCelgeneEuropeOncologyPricingRare diseasesRegulationResearchRevlimid

Tengion closes deals to advance organ regeneration platform

09-07-2013

USA-based Tengion (OTCQB: TNGN), a leader in regenerative medicine, says it has now closed transactions…

BiotechnologyCelgeneFinancialLicensingResearchTengion

Onyx Pharma rejects Amgen's unsolicited $120 per share takeover offer

01-07-2013

Following a day of speculation and rumor on Friday, US biotech firm Onyx Pharmaceuticals (Nasdaq: ONXX)…

AmgenBayerBiotechnologyCelgeneMergers & AcquisitionsOncologyOnyx PharmaceuticalsPfizerRoche

MorphoSys and Celgene in deal to advance MOR202 for multiple myeloma

27-06-2013

German biotech firm MorphoSys (FSE: MOR) and USA-based Celgene (Nasdaq: CELG), the world's largest independent…

BiotechnologyCelgeneEuropeLicensingMergers & AcquisitionsMOR202MorphoSysOncology

Bionor Pharma leaps on positive trial results of HIV vaccine Vacc-4x with Revlimid

14-06-2013

Norway-based Bionor Pharma (OSE: BIONOR) saw its shares leap 16% to 3.67 kroner on June 13, after the…

Anti-viralsBionor PharmaCelgenePharmaceuticalResearchRevlimidVacc-4xVaccines

19 to 43 of 91 results

Back to top